Zika virus (ZIKV) is an emerging vector-borne virus that is associated with severe congenital cerebral anomalies in fetuses and paralytic Guillain-Barré syndrome in adults. In the current global health crisis, there are no vaccines or therapeutics available for the treatment of ZIKV infection. In the present study, we evaluated the efficacy of the protoberberine alkaloid, palmatine, in inhibiting ZIKV and Japanese encephalitis virus (JEV). Palmatine was shown to bind to restricted viruses, inhibit ZIKV infection, and resist ZIKV-induced cytopathic effects. Palmatine was also shown to inhibit JEV infection in multiple cell lines. Overall, the effects of palmatine in disrupting ZIKV binding, entry, and stability indicate that this small molecule would be a good starting point for the development of treatments aimed at inhibiting ZIKV infection.
Palmatine inhibits Zika virus infection by disrupting virus binding, entry, and stability.
Yi-Jung Ho,Jeng-Wei Lu,Yu-Ling Huang,Zheng-Zong Lai
Published 2019 in Biochemical and Biophysical Research Communications - BBRC
ABSTRACT
PUBLICATION RECORD
- Publication year
2019
- Venue
Biochemical and Biophysical Research Communications - BBRC
- Publication date
2019-10-22
- Fields of study
Biology, Medicine, Environmental Science
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-46 of 46 references · Page 1 of 1
CITED BY
Showing 1-36 of 36 citing papers · Page 1 of 1